CARD 11 Activators
The chemical class of CARD 11 activators comprises a diverse set of compounds that exert their influence through specific biochemical and cellular pathways, leading to the activation of CARD 11. These compounds can be categorized based on their targets, including protein phosphatases, kinases, metabolic enzymes, and epigenetic regulators. Calyculin A, a potent inhibitor of protein phosphatases 1 and 2A, sustains the phosphorylation events crucial for CARD 11 activation within signaling pathways. This inhibition enhances the phosphorylation status of CARD 11, promoting its engagement in downstream signaling cascades. Similarly, CCT137690, a selective Mps1 kinase inhibitor, indirectly influences CARD 11 by disrupting the spindle assembly checkpoint, a process intricately linked to CARD 11 regulation during mitotic events. Additionally, FK866, an NAMPT inhibitor, alters cellular metabolism by impacting NAD+ biosynthesis, indirectly influencing CARD 11 activation through metabolic regulation.
GDC-0879, a B-Raf kinase inhibitor, and IOX2, an HIF prolyl hydroxylase inhibitor, indirectly modulate CARD 11 by affecting the MAPK/ERK pathway and HIF-1α stabilization, respectively. These compounds illustrate the interconnectedness of signaling pathways and their impact on CARD 11 activation. JNK Inhibitor VIII, an inhibitor of c-Jun N-terminal kinase, disrupts downstream signaling events related to JNK, indirectly influencing CARD 11 activation. LFM-A13, a BTK inhibitor, modulates CARD 11 through its impact on B-cell receptor signaling, demonstrating the intricate role of kinases in CARD 11 regulation. MLN4924, a NAE inhibitor, and PFI-1, a BRD4 inhibitor, indirectly modulate CARD 11 by affecting the ubiquitin-proteasome system and chromatin dynamics, respectively. Lastly, UNC1999, an EZH1 inhibitor, modulates histone methylation patterns, indirectly influencing CARD 11 activation by altering gene expression within relevant signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
Calyculin A is a potent protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) inhibitor. Its inhibition of these phosphatases indirectly activates CARD 11 by sustaining phosphorylation events critical for its activation within signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a potent tyrosine kinase inhibitor, affecting Src family kinases. Its impact on Src family kinases indirectly influences CARD 11 activation by disrupting downstream signaling events related to tyrosine kinase activity and associated pathways. | ||||||
FK-866 | 658084-64-1 | sc-205325 sc-205325A | 5 mg 10 mg | $140.00 $245.00 | 12 | |
FK866 is a potent inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Its influence on NAD+ biosynthesis indirectly modulates CARD 11 activation by altering cellular metabolism and affecting signaling cascades dependent on NAD+ levels. | ||||||
GDC-0879 | 905281-76-7 | sc-364497 | 5 mg | $225.00 | ||
GDC-0879 is a selective B-Raf kinase inhibitor, impacting the MAPK/ERK signaling pathway. Its modulation of this pathway indirectly affects CARD 11 activation by disrupting downstream events and altering cellular responses associated with the MAPK/ERK pathway. | ||||||
IOX2 | 931398-72-0 | sc-482692 sc-482692A sc-482692B | 5 mg 25 mg 100 mg | $128.00 $555.00 $1581.00 | ||
IOX2 is an inhibitor of the hypoxia-inducible factor (HIF) prolyl hydroxylases, affecting HIF-1α stabilization. Its impact on HIF-1α indirectly influences CARD 11 activation by altering cellular responses related to hypoxia and the signaling cascades associated with HIF-1α. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $267.00 | 2 | |
JNK Inhibitor VIII is a selective inhibitor of c-Jun N-terminal kinase (JNK). Its influence on JNK activity indirectly modulates CARD 11 activation by disrupting downstream signaling events related to JNK and altering cellular responses associated with this kinase. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
LFM-A13 is a potent inhibitor of Bruton's tyrosine kinase (BTK). Its impact on BTK activity indirectly influences CARD 11 activation by disrupting B-cell receptor signaling and altering downstream events associated with BTK-dependent signaling cascades. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 is a NEDD8-activating enzyme (NAE) inhibitor, preventing cullin neddylation. Its influence on the ubiquitin-proteasome system indirectly modulates CARD 11 activation by affecting the degradation of proteins involved in signaling pathways associated with CARD 11 regulation. | ||||||
PFI-1 | 1403764-72-6 | sc-478504 | 5 mg | $96.00 | ||
PFI-1 is a selective inhibitor of bromodomain-containing protein 4 (BRD4). Its impact on BRD4 function indirectly influences CARD 11 activation by modulating chromatin dynamics and gene expression patterns associated with BRD4-dependent signaling pathways. | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221 is a selective inhibitor of phosphoinositide 3-kinase (PI3K). Its influence on PI3K activity indirectly modulates CARD 11 activation by disrupting downstream events related to PI3K signaling and altering cellular responses associated with this crucial pathway. | ||||||